Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Raine

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
The Review of Diabetic Studies : RDS|October 7, 2009
Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populationsJenny M Phillips, Nicole M Parish, Tim Raine, et al.
Journal of Clinical Medicine|February 13, 2025
A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International SurveyMohmmed Tauseef Sharip, Biljana Brezina, Juan De La Revilla Negro, et al.
United European Gastroenterology Journal|March 5, 2026
Corticosteroid Use in Childhood-Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006-2022)Karl Mårild, Mikkel Malham, Petter Malmborg, et al.
American Journal of Physiology. Cell Physiology|October 20, 2025
Protease-activated receptor 1-mediated matrix metalloprotease signaling in sensory neuronsKatie J Williams, Giulia Galimberti, James P Higham, et al.
Journal of Comparative Effectiveness Research|February 24, 2025
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Journal of Comparative Effectiveness Research|March 17, 2025
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Inflammatory Bowel Diseases|December 2, 2025
Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResourceKaung Yan, Sudheer Kumar Vuyyuru, Adam Taylor, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial ProgrammeTim Raine, Yoh Ishiguro, David T Rubin, et al.
Inflammatory Bowel Diseases|April 1, 2023
Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysisSudheer K Vuyyuru, Tran M Nguyen, Malcolm Hogan, et al.
Journal of Crohn'S & Colitis|June 20, 2020
Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative StudyAndreas Zollner, Andreas Schmiderer, Simon J Reider, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
The Review of Diabetic Studies : RDS|October 7, 2009
Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populationsJenny M Phillips, Nicole M Parish, Tim Raine, et al.
Journal of Clinical Medicine|February 13, 2025
A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International SurveyMohmmed Tauseef Sharip, Biljana Brezina, Juan De La Revilla Negro, et al.
United European Gastroenterology Journal|March 5, 2026
Corticosteroid Use in Childhood-Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006-2022)Karl Mårild, Mikkel Malham, Petter Malmborg, et al.
American Journal of Physiology. Cell Physiology|October 20, 2025
Protease-activated receptor 1-mediated matrix metalloprotease signaling in sensory neuronsKatie J Williams, Giulia Galimberti, James P Higham, et al.
Journal of Comparative Effectiveness Research|February 24, 2025
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Journal of Comparative Effectiveness Research|March 17, 2025
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Inflammatory Bowel Diseases|December 2, 2025
Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResourceKaung Yan, Sudheer Kumar Vuyyuru, Adam Taylor, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial ProgrammeTim Raine, Yoh Ishiguro, David T Rubin, et al.
Inflammatory Bowel Diseases|April 1, 2023
Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysisSudheer K Vuyyuru, Tran M Nguyen, Malcolm Hogan, et al.
Journal of Crohn'S & Colitis|June 20, 2020
Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative StudyAndreas Zollner, Andreas Schmiderer, Simon J Reider, et al.
Pageof 11